Cancer Cell Imaging

About

INVENTION Novelty of the invention rests in the novel use of biocompatible nanoparticles with Aggregation Induced Emission (AIE) characteristics as fluorescent bioprobes for cell imaging. Formulation of these red fluorescent emitters using biomacromolecule matrix yield uniformly sized nanoparticles (NPs) with high brightness and low cytotoxicity. These probes have been tested by using breast cancer cell and tumour bearing mice in in vivo experiment. When compared with the conventional cell imaging technology, competitive advantage of these probes lies in its ability to trace cell in a real time and non-invasive manner. MARKET OPPORTUNITY This invention is fundamental. It opens up a new avenue for the development of AIE-active biocompatible NP-based probes for clinical cancer imaging. These probes can potentially be used for visualization of tumor for cancer diagnosis and therapeutics with high tissue penetration. Key Benefits Excellent cancer cell uptake and prominent tumor targeting ability Excellent candidate materials for clinical cancer imaging and diagnostics